KIR2DL1 and ovarian carcinoma: In line with previous results describing the expansion of KIR2DL1+ CD8+ T cells in nonmetastatic melanoma patients [14], the data in this manuscript show that HLA C2-ligands drove the expansion of KIR2DL1+ CD8+ T lymphocytes in patients with 3 different types of solid cancers (melanoma, ovarian carcinoma and bladder carcinoma).